Andrea Giustina
#116,459
Most Influential Person Now
Researcher
Andrea Giustina's AcademicInfluence.com Rankings
Andrea Giustinabiology Degrees
Biology
#6772
World Rank
#9562
Historical Rank
Biotechnology
#68
World Rank
#69
Historical Rank
Molecular Biology
#722
World Rank
#739
Historical Rank
Download Badge
Biology
Andrea Giustina's Degrees
- Bachelors Biology University of Milan
- Masters Biotechnology University of Milan
- PhD Molecular Biology University of Milan
Similar Degrees You Can Earn
Why Is Andrea Giustina Influential?
(Suggest an Edit or Addition)Andrea Giustina's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. (1998) (1201)
- Diagnosis and complications of Cushing's syndrome: a consensus statement. (2003) (1010)
- Criteria for cure of acromegaly: a consensus statement. (2000) (1006)
- Glucocorticoid-induced osteoporosis: pathophysiology and therapy (2007) (956)
- Growth hormone, insulin-like growth factors, and the skeleton. (2008) (781)
- A consensus on criteria for cure of acromegaly. (2010) (712)
- Guidelines for acromegaly management: an update. (2009) (704)
- Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas (2006) (679)
- Mechanisms of anabolic therapies for osteoporosis. (2007) (599)
- Skeletal and Extraskeletal Actions of Vitamin D: Current Evidence and Outstanding Questions (2018) (495)
- Glucocorticoid-induced osteoporosis: an update (2006) (453)
- Expert consensus document: A consensus on the medical treatment of acromegaly (2014) (372)
- Guidelines for acromegaly management. (2002) (338)
- A Consensus Statement on acromegaly therapeutic outcomes (2018) (325)
- High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. (2006) (324)
- A consensus on the diagnosis and treatment of acromegaly complications (2012) (289)
- Drug-induced osteoporosis: mechanisms and clinical implications. (2010) (246)
- Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. (2008) (243)
- Perspectives on glucocorticoid-induced osteoporosis. (2004) (228)
- Consensus statement: medical management of acromegaly. (2005) (227)
- Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia. (2008) (221)
- Microbiota and metabolic diseases (2018) (215)
- Primary empty sella. (2005) (213)
- Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. (2001) (208)
- Ghrelin regulates proliferation and differentiation of osteoblastic cells. (2005) (201)
- MECHANISMS IN ENDOCRINOLOGY: Vitamin D and COVID-19 (2020) (201)
- Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. (2009) (199)
- COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology (2020) (188)
- Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement (2017) (179)
- Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement (2017) (179)
- Vitamin D assays and the definition of hypovitaminosis D: results from the First International Conference on Controversies in Vitamin D (2018) (178)
- Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly (2012) (174)
- Diabetes in Cushing syndrome: basic and clinical aspects (2011) (164)
- Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. (2014) (157)
- Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross‐Sectional Study in Postmenopausal Women (2005) (156)
- Hyperprolactinemia and prolactinomas. (2008) (154)
- A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. (2020) (151)
- Consensus statement from 2nd International Conference on Controversies in Vitamin D (2020) (144)
- Basic counterpoint: mechanisms and pathways of gonadal steroid modulation of growth hormone secretion. (1992) (141)
- Glucocorticoids and the regulation of growth hormone secretion (2013) (141)
- Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. (2019) (140)
- New understanding and treatments for osteoporosis (2012) (140)
- Prevalence of vertebral fractures in men with acromegaly. (2008) (139)
- Glucocorticoid-induced osteoporosis: summary of a workshop. (2001) (138)
- Consensus on diagnosis and management of Cushing's disease: a guideline update. (2021) (138)
- Femtocells: Opportunities and Challenges for Business and Technology (2009) (138)
- Controversies in Vitamin D: Summary Statement From an International Conference (2018) (137)
- Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. (2015) (134)
- Cushing's Syndrome and Bone (2005) (132)
- Long‐term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly (2002) (130)
- Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. (2007) (130)
- Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. (2015) (129)
- Vertebral fractures in patients with acromegaly: a 3-year prospective study. (2013) (128)
- Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease. (2008) (127)
- Recombinant Human TSH Modulates In Vivo C‐Telopeptides of Type‐1 Collagen and Bone Alkaline Phosphatase, but Not Osteoprotegerin Production in Postmenopausal Women Monitored for Differentiated Thyroid Carcinoma (2004) (127)
- Hypocalcemia is highly prevalent and predicts hospitalization in patients with COVID-19 (2020) (127)
- The role of glucocorticoids in the regulation of growth hormone secretion Mechanisms and clinical significance (1992) (126)
- Haemodynamic effects of intravenous growth hormone in congestive heart failure (1997) (124)
- Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy (2006) (122)
- Endocrine and metabolic aspects of the COVID-19 pandemic (2020) (120)
- Clinical review: Growth hormone and cardiovascular risk factors. (2005) (120)
- Diagnosis and treatment of acromegaly complications (2003) (117)
- Pituitary Diseases and Bone (2018) (117)
- Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update. (2014) (114)
- Multidisciplinary management of acromegaly: A consensus (2020) (112)
- Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. (2010) (107)
- Maturation of the regulation of growth hormone secretion in young males with hypogonadotropic hypogonadism pharmacologically exposed to progressive increments in serum testosterone. (1997) (105)
- High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. (2009) (105)
- Pituitary tumours: inflammatory and granulomatous expansive lesions of the pituitary. (2009) (101)
- Glucocorticoid-induced Osteoporosis (2000) (96)
- The role of patient education in the prevention and management of type 2 diabetes: an overview (2016) (95)
- Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis (2019) (95)
- Current management practices for acromegaly: an international survey (2011) (93)
- Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults (2008) (92)
- Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. (2008) (91)
- Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review (2009) (91)
- A Pituitary Society update to acromegaly management guidelines (2020) (90)
- Influence of thyroid hormones on the regulation of growth hormone secretion. (1995) (89)
- Controversies in Vitamin D: A Statement From the Third International Conference (2020) (87)
- Current and Emerging Aspects of Diabetes Mellitus in Acromegaly (2016) (86)
- Clinical review 136: Primary lymphoma of the pituitary: an emerging clinical entity. (2001) (85)
- Leptin regulates GH gene expression and secretion and nitric oxide production in pig pituitary cells. (2002) (80)
- Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement (2022) (80)
- Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. (1995) (79)
- Vertebral fractures in males with prolactinoma (2011) (78)
- Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. (1989) (78)
- Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines (2016) (76)
- Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. (2009) (74)
- Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. (1990) (73)
- Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. (1995) (70)
- Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. (2009) (69)
- Treatment of Cushing disease: overview and recent findings (2010) (69)
- Resistance to somatostatin analogs in acromegaly: An evolving concept? (2006) (68)
- Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. (1996) (68)
- Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. (2005) (68)
- Dehydroepiandrosterone sulfate enhances natural killer cell cytotoxicity in humans via locally generated immunoreactive insulin-like growth factor I. (1999) (65)
- Growth hormone deficiency in the adult (2006) (64)
- High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas (2011) (63)
- Acromegalic Patients Show the Presence of Hypertrophic Remodeling of Subcutaneous Small Resistance Arteries (2004) (62)
- Influence of type 2 diabetes on functional and structural properties of coronary artery bypass conduits. (2003) (61)
- Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. (2002) (59)
- Mechanism of action of hexarelin and GHRP-6: analysis of the involvement of GHRH and somatostatin in the rat. (1995) (59)
- Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. (2010) (58)
- Effects of food deprivation on the GH axis: immunocytochemical and molecular analysis. (1997) (57)
- High prevalence of radiological vertebral fractures in HIV-infected males (2012) (56)
- Influence of diabetes mellitus on vertebral fractures in men with acromegaly (2011) (54)
- Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. (1992) (54)
- Bone and Joint Disorders in Acromegaly (2015) (54)
- High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. (2004) (53)
- COVID-19 and endocrine and metabolic diseases. An updated statement from the European Society of Endocrinology (2021) (52)
- Type 2 diabetes mellitus is associated with faster degeneration of bioprosthetic valve: results from a propensity score-matched Italian multicenter study. (2012) (52)
- Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects (2006) (51)
- Effects of sex and age on the growth hormone response to galanin in healthy human subjects. (1993) (51)
- Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes (2020) (50)
- Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency (2016) (50)
- MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. (2017) (50)
- Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man. (1990) (49)
- Physiological role of galanin in the regulation of anterior pituitary function in humans. (1994) (49)
- COVID-19 and the pituitary (2021) (48)
- Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects. (1990) (48)
- SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study (2015) (48)
- Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. (1999) (48)
- High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures (2016) (48)
- Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: relevant clinical aspects. (2001) (48)
- The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly (2007) (46)
- Pegvisomant in acromegaly: an update (2017) (46)
- Hypocalcemia in COVID-19: Prevalence, clinical significance and therapeutic implications (2021) (46)
- A tale of pituitary adenomas: to NET or not to NET (2019) (46)
- Short term effect of captopril on microalbuminuria induced by exercise in normotensive diabetics. (1989) (45)
- Effects of pyridostigmine on spontaneous and growth hormone‐releasing hormone stimulated growth hormone secretion in children on daily glucocorticoid therapy after liver transplantation (1991) (45)
- Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline (2014) (45)
- Differential Inhibition of Growth Hormone Secretion by Analogs Selective for Somatostatin Receptor Subtypes 2 and 5 in Human Growth-Hormone-Secreting Adenoma Cells in vitro (2001) (44)
- Decreased Release of the Angiogenic Peptide Vascular Endothelial Growth Factor in Alzheimer’s Disease: Recovering Effect with Insulin and DHEA Sulfate (2004) (44)
- Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes (2011) (44)
- High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study (2017) (43)
- The epidemiology of osteoporosis in Italian postmenopausal women according to the National Bone Health Alliance (NBHA) diagnostic criteria: a multicenter cohort study (2018) (42)
- Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy. (2011) (42)
- Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects. (2007) (42)
- Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus (2012) (41)
- Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly (2009) (41)
- Leptin Stimulates Growth Hormone Secretion via a Direct Pituitary Effect Combined with a Decreased Somatostatin Tone in a Median Eminence-Pituitary Perifusion Study (2004) (41)
- Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency (2007) (40)
- Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA (2007) (39)
- Role of growth hormone in chronic heart failure: therapeutic implications. (2000) (39)
- Sexual Dimorphism of Coronavirus 19 Morbidity and Lethality (2020) (38)
- MANAGEMENT OF ENDOCRINE DISEASE: Therapeutics of Vitamin D. (2018) (38)
- Pegvisomant in acromegaly: Why, when, how (2007) (37)
- Growth hormone neuroregulation in diabetes mellitus (1994) (37)
- High prevalence of radiological vertebral fractures in adult patients with Ehlers-Danlos syndrome. (2016) (37)
- Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement. (1992) (37)
- Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. (1995) (37)
- Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide (2020) (36)
- Parathyroid hormone pulsatility: physiological and clinical aspects (2015) (36)
- Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. (1998) (36)
- High Prevalence of Radiological Vertebral Fractures in Women on Thyroid-Stimulating Hormone–Suppressive Therapy for Thyroid Carcinoma (2017) (36)
- Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with type 2 diabetes mellitus. (2006) (35)
- Transcutaneous Oxygen Tension as a Potential Predictor of Cardiovascular Events in Type 2 Diabetes (2013) (34)
- Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. (2022) (34)
- The Modern Criteria for Medical Management of Acromegaly. (2016) (34)
- GH deficiency in the adult and bone. (2005) (34)
- Modulation by galanin of growth hormone and gonadotropin secretion from perifused pituitary and median eminence of prepubertal male calves. (1997) (34)
- Severe hypocalcemia in a thyroidectomized woman with Covid-19 infection (2020) (33)
- Hypocalcemia is a distinctive biochemical feature of hospitalized COVID-19 patients (2020) (33)
- Relationship between instrumental activities of daily living and blood glucose control in elderly subjects with type 2 diabetes. (2008) (32)
- Impaired growth hormone (GH) response to pyridostigmine in type 1 diabetic patients with exaggerated GH-releasing hormone-stimulated GH secretion. (1990) (32)
- Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients (2006) (32)
- Immunocytochemical and molecular analysis of the effects of glucocorticoid treatment on the hypothalamic-somatotropic axis in the rat. (1996) (32)
- Octreotide for acromegaly treatment: a reappraisal (2013) (31)
- The Changing Clinical Spectrum of Hypophysitis (2019) (30)
- Possible delayed diagnosis and treatment of metastatic differentiated thyroid cancer by adopting the 2015 ATA guidelines. (2018) (30)
- Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. (2014) (30)
- Should we abandon statins in the prevention of bone fractures? (2013) (30)
- Androgens and body composition in the aging male. (2005) (29)
- Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors (2014) (29)
- Low-dose acyclovir and acute renal failure. (1988) (29)
- Diabetes in Cushing Disease (2017) (29)
- Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. (2005) (29)
- Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients (2012) (28)
- Sex-Steroid Interactions with Growth Hormone (2012) (28)
- Vitamin D: Dosing, levels, form, and route of administration: Does one approach fit all? (2021) (28)
- Clinical Biology of the Pituitary Adenoma (2022) (28)
- Effects of tamoxifen on GH and IGF-I levels in acromegaly (1997) (28)
- Real-life management and outcome of thyroid carcinoma-related bone metastases: results from a nationwide multicenter experience (2017) (28)
- Thyroid Autoimmunity and Spontaneous Cervical Artery Dissection (2006) (28)
- Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. (2017) (28)
- Reciprocal relationship between the level of circulating cortisol and growth hormone secretion in response to growth hormone-releasing hormone in man: studies in patients with adrenal insufficiency. (1994) (27)
- Growth hormone in glucocorticoid-induced osteoporosis. (2002) (27)
- Short-Term Administration of Captopril and Nifedipine and Exercise-Induced Albuminuria in Normotensive Diabetic Patients With Early-Stage Nephropathy (1990) (27)
- Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. (2000) (27)
- Acromegalic osteopathy (2016) (27)
- Erectile dysfunction and coronary artery disease in patients with diabetes. (2011) (27)
- Current and future medical treatments for patients with acromegaly (2016) (27)
- Development of isolated ACTH deficiency in a man with type I diabetes mellitus (1988) (27)
- Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy Volunteers (1995) (26)
- The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man. (1991) (25)
- Effect of pyridostigmine on the growth hormone response to growth hormone-releasing hormone in lean and obese type II Diabetic patients. (1994) (25)
- IGF-I, IGFBP-2 and -3 but not GH concentrations are different in normal and poor growing piglets. (2001) (25)
- Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients. (2002) (25)
- Prevalence of morphometric vertebral fractures in “difficult” patients with acromegaly with different biochemical outcomes after multimodal treatment (2018) (25)
- Vitamin D levels associate with blood glucose and BMI in COVID-19 patients predicting disease severity (2021) (25)
- Glucocorticoid-induced osteoporosis and parathyroid hormone. (2010) (25)
- Are women with osteoporosis treated with denosumab at risk of severe COVID-19? (2020) (25)
- Picotamide, a Dual TXB Synthetase Inhibitor and TXB Receptor Antagonist, Reduces Exercise-Induced Albuminuria in Microalbuminuric Patients With NIDDM (1993) (25)
- Effects of Pegvisomant and Pasireotide LAR on vertebral fractures in acromegaly resistant to First-Generation SRLs. (2020) (25)
- GH receptor isoforms and skeletal fragility in acromegaly. (2014) (24)
- Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure. (2012) (24)
- Effect of galanin on growth hormone-releasing hormone-stimulated growth hormone secretion in adult patients with nonendocrine diseases on long-term daily glucocorticoid treatment. (1992) (24)
- Primary empty sella: Why and when to investigate hypothalamic-pituitary function. (2010) (24)
- Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19 (2020) (23)
- Acromegaly and Vertebral Fractures: Facts and Questions (2020) (23)
- Effects of short-term glucocorticoid deprivation on growth hormone (GH) response to GH-releasing hormone in man. (1989) (23)
- Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly (2017) (23)
- Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D (2021) (23)
- Cardiovascular Effects of a Single Slow Release Lanreotide Injection in Patients with Acromegaly and Left Ventricular Hypertrophy (1999) (23)
- Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. (2007) (23)
- Optimal use of pegvisomant in acromegaly: are we getting there? (2015) (23)
- Pituitary Tumors Centers of Excellence. (2020) (23)
- Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects. (1992) (23)
- Bone safety of dual-release hydrocortisone in patients with hypopituitarism (2018) (23)
- Predictors of healing, ulcer recurrence and persistence, amputation and mortality in type 2 diabetic patients with diabetic foot: a 10-year retrospective cohort study (2020) (22)
- Hypothalamic regulation of impaired growth hormone secretion in diabetic rats. 1. Studies in streptozotocin-induced diabetic rats. (1992) (22)
- The pharmacological aspects of the treatment of acromegaly. (1996) (22)
- Current Guidelines for Adult GH Replacement (2005) (22)
- Hypocalcemia in COVID-19 is associated with low vitamin D levels and impaired compensatory PTH response (2021) (21)
- Growth, Insulin-Like Growth Factor I (IGF-I), and IGF-Binding Proteins 1 and 3 in Children with Severe Liver Disease before and after Liver Transplantation: A Longitudinal and Cross-Sectional Study (1998) (21)
- Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? (2013) (21)
- Changes in the growth hormone axis due to exercise training in male and female rats: secretory and molecular responses. (1995) (21)
- Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects (2017) (21)
- The emerging osteo-metabolic phenotype of COVID-19: clinical and pathophysiological aspects (2021) (20)
- Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease. (1991) (20)
- CONSENSUS Guidelines for Acromegaly Management (2002) (20)
- Comparative effect of clonidine and growth hormone (GH)-releasing hormone on GH secretion in adult patients on chronic glucocorticoid therapy. (1992) (20)
- Skeletal Fragility in Endogenous Hypercortisolism. (2016) (20)
- Primary empty sella: Why and when to investigate hypothalamic-pituitary function (2010) (20)
- Vitamin D in Osteosarcopenic Obesity (2022) (19)
- Occurrence and response to treatment of Graves’ disease after COVID vaccination in two male patients (2021) (19)
- Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection (2014) (19)
- Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. (2014) (19)
- Low-dose octreotide is able to cause a maximal inhibition of the glycemic responses to a mixed meal in obese type 2 diabetic patients treated with insulin. (1991) (19)
- Insulin and GH–IGF-I axis: endocrine pacer or endocrine disruptor? (2015) (19)
- GH-releasing peptides and bone. (2005) (19)
- Staging and managing patients with acromegaly in clinical practice: baseline data from the SAGIT® validation study (2019) (19)
- Galanin decreases circulating growth hormone levels in acromegaly. (1992) (18)
- Hypovitaminosis D and the endocrine phenotype of COVID-19 (2021) (18)
- Treatment of hypoparathyroidism. (2018) (18)
- Growth hormone deficiency in treated acromegaly (2015) (18)
- Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy (2019) (18)
- Role of structured individual patient education in the prevention of vascular complications in newly diagnosed type 2 diabetes: the INdividual Therapeutic Education in Newly Diagnosed type 2 diabetes (INTEND) randomized controlled trial (2018) (18)
- Effect of GHRP-6 and GHRH on GH secretion in rats following chronic glucocorticoid treatment. (1995) (18)
- Low T3 syndrome and outcome in elderly hospitalized geriatric patients. (2002) (18)
- Effects of Medical Treatment of Prostate Cancer on Bone Health (2021) (18)
- Growth hormone secretagogue (GHS) analogue, hexarelin stimulates GH from peripheral lymphocytes. (2002) (18)
- Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. (2002) (18)
- : Growth Hormone and Cardiovascular Risk Factors (2005) (18)
- Adiponectin to leptin ratio reflects inflammatory burden and survival in COVID-19 (2021) (18)
- Weight trajectories and abdominal adiposity in COVID-19 survivors with overweight/obesity (2021) (18)
- Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel (2021) (18)
- Exercise-induced microalbuminuria in patients with active acromegaly: acute effects of slow-release lanreotide, a long-acting somatostatin analog. (2000) (17)
- Transformation of a MGUS to Overt Multiple Myeloma: The Possible Role of a Pituitary Macroadenoma Secreting High Levels of Insulin-like Growth Factor 1 (IGF-1) (2003) (17)
- Effects of exogenous growth hormone pretreatment on the pituitary growth hormone response to growth hormone-releasing hormone alone or in combination with pyridostigmine in type I diabetic patients. (1991) (17)
- Hypothalamic regulation of growth hormone secretion during food deprivation in the rat. (1993) (17)
- Risk of vertebral fractures in hypoparathyroidism (2019) (17)
- How to improve effectiveness of pegvisomant treatment in acromegalic patients (2018) (17)
- Hyperprolactinemia and bone (2020) (16)
- Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism (2019) (16)
- Effects of galanin on growth hormone and prolactin secretion in anorexia nervosa. (2000) (16)
- Comparative effect of porcine and rat galanin on growth hormone secretion in normal adult men. (1992) (16)
- Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era (2021) (16)
- Effects of metformin on cell growth and AMPK activity in pituitary adenoma cell cultures, focusing on the interaction with adenylyl cyclase activating signals (2017) (16)
- Vitamin D-binding protein: one more piece in the puzzle of acromegalic osteopathy? (2016) (15)
- AMP-activated protein kinase regulates normal rat somatotroph cell function and growth of rat pituitary adenomatous cells (2011) (15)
- Albuminuria induced by exercise in hypertensive type I and type II diabetic patients: a randomised, double-blind study on the effects of acute administration of captopril and nifedipine. (1991) (15)
- EXTENSIVE CLINICAL EXPERIENCE Primary Empty Sella (2005) (15)
- Pituitary diseases and bone. (2015) (15)
- The management of the patient with acromegaly and headache: A still open clinical challenge (2008) (15)
- Growth hormone deficiency in treated acromegaly and active Cushing's syndrome. (2017) (15)
- Development of a meningioma in a patient with acromegaly during octreotide treatment: Are there any causal relationships? (2003) (15)
- Characterization of the paradoxical growth hormone inhibitory effect of galanin in acromegaly. (1995) (15)
- Role of vitamin D in diabetic retinopathy: Pathophysiological and clinical aspects (2020) (15)
- Treatment of glucocorticoid-induced osteoporosis (2009) (15)
- Treatment of hypothyroidism: all that glitters is gold? (2016) (15)
- Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response. (2020) (14)
- Acromegaly consensus: the next steps. (2003) (14)
- High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma (2018) (14)
- Glucocorticoid inhibition of growth in rats: partial reversal with the full-length ghrelin analog BIM-28125 (2007) (14)
- Active acromegaly enhances spontaneous parathyroid hormone pulsatility. (2006) (14)
- The tale in evolution: clarity, consistency and consultation, not contradiction and confusion (2020) (14)
- New oral anticoagulants and pituitary apoplexy (2016) (14)
- Effects of recombinant follicle-stimulating hormone on bone turnover markers in infertile women undergoing in vitro fertilization procedure. (2013) (14)
- Diagnosis and treatment of acromegaly and its complications: consensus guidelines. (2005) (14)
- Role of galanin in the regulation of somatotrope and gonadotrope function in young ovulatory women. (1995) (13)
- Effects of repeated doses and continuous infusions of the growth hormone-releasing peptide hexarelin in conscious male rats. (1998) (13)
- Inhibitory effects of galanin on growth hormone (GH) release in cultured GH-secreting adenoma cells: comparative study with octreotide, GH-releasing hormone, and thyrotropin-releasing hormone. (1997) (13)
- Growth hormone receptor isoforms and fracture risk in adult‐onset growth hormone‐deficient patients (2016) (13)
- Effects of AMPK activation and combined treatment with AMPK activators and somatostatin on hormone secretion and cell growth in cultured GH-secreting pituitary tumor cells (2013) (13)
- Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease. (1993) (13)
- Effect of two β2-agonist drugs, salbutamol and broxaterol, on the growth hormone response to exercise in adult patients with asthmatic bronchitis (1995) (13)
- The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): A surgical perspective (2020) (13)
- Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment (2012) (13)
- A retrospective hormonal and immunohistochemical evaluation of 47 acromegalic patients: prognostic value of preoperative plasma prolactin. (2002) (13)
- COVID-19 and hypopituitarism (2021) (13)
- New medical therapies of acromegaly. (2016) (12)
- Bone ultrasonometric features and growth hormone secretion in asthmatic patients during chronic inhaled corticosteroid therapy. (2006) (12)
- Role of AMP‐Activated Protein Kinase Activators in Antiproliferative Multi‐Drug Pituitary Tumour Therapies: Effects of Combined Treatments with Compounds Affecting the mTOR‐p70S6 Kinase Axis in Cultured Pituitary Tumour Cells (2015) (12)
- Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect (2014) (12)
- Growth hormone deficiency and cardiovascular risk: do we need additional markers? (2012) (12)
- Growth hormone replacement therapy and fracture risk. (2015) (11)
- Points of integration between the intracellular energy sensor AMP-activated protein kinase (AMPK) activity and the somatotroph axis function (2012) (11)
- Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group (2011) (11)
- Effect of hydrocortisone on the growth hormone response to growth hormone-releasing hormone in acromegaly. (1994) (11)
- Keep an eye on nonfunctioning pituitary adenomas (2012) (11)
- Role of Growth Hormone in Chronic Heart Failure (2000) (11)
- Biochemical Evaluation of Patients with Active Acromegaly and Type 2 Diabetes Mellitus: Efficacy and Safety of the Galanin Test (2008) (11)
- Inhibitory effect of galanin on growth hormone release from rat pituitary tumor cells (GH1) in culture. (1994) (11)
- Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome (2018) (11)
- Galanin counteracts the inhibitory effects of glucocorticoids on growth hormone secretion in the rat. (1995) (11)
- Prevention and treatment of glucocorticoid-induced osteoporosis. (2008) (10)
- Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. (2005) (10)
- Cardiovascular risk in aging and obesity: Is there a role for GH? (2005) (10)
- Thyrotropin and prolactin secretion are not affected by porcine and rat galanin in normal subjects. (1992) (10)
- Hexarelin, a novel GHRP-6 analog, stimulates growth hormone (GH) release in a GH-secreting rat cell line (GH1) insensitive to GH-releasing hormone (1997) (10)
- The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy (2020) (10)
- Effects of benfluorex on glucose tolerance, metabolic control, beta-cell secretion, and peripheral sensitivity to insulin in obese type II diabetic patients on a body weight-maintaining diet (1989) (10)
- Evaluation of Muscle Mass and Stiffness with Limb Ultrasound in COVID-19 Survivors (2022) (9)
- Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion. (2000) (9)
- Commentary: Postsurgical monitoring of acromegaly. (2013) (9)
- International Multicenter Validation Study of the SAGIT ® Instrument in Acromegaly. (2021) (9)
- Fat utilization and arterial hypertension in overweight/obese subjects (2013) (9)
- Effects of the selective estrogen receptor modulator LY117018 on growth hormone secretion: In vitro studies. (2004) (9)
- [Hypopituitarism secondary to suprasellar giant carotido-ophthalmic aneurysm. Normalization of the hypophyseal function after neurosurgical depression of the aneurysm]. (1989) (9)
- Diagnosis and management of prolactinomas: current challenges (2020) (9)
- Adrenergic and cholinergic involvement in basal and growth hormone-releasing hormone-stimulated growth hormone secretion in glucocorticoid-treated rats. (1995) (9)
- Hypothalamic control of growth hormone (GH) secretion in type I diabetic men: effect of the combined administration of GH-releasing hormone and hexarelin, a novel GHRP-6 analog. (1996) (9)
- Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study (2008) (8)
- EFFECTS OF INTRANASAL CALCITONIN ADMINISTRATION ON PITUITARY GH RESPONSE TO hGHRH (1–29)NH2 IN NORMAL ADULT SUBJECTS (1989) (8)
- Effect of pretreatment with pyridostigmine on the thyrotropin response to thyrotropin-releasing hormone in patients with Cushing's disease. (1992) (8)
- Arginine blocks the inhibitory effect of hydrocortisone on circulating growth hormone levels in patients with acromegaly. (1993) (8)
- TREATMENT WITH METFORMIN IS PROTECTIVE AGAINST LIMITATIONS IN INSTRUMENTAL ACTIVITIES OF DAILY LIVING IN OLDER SUBJECTS WITH TYPE 2 DIABETES MELLITUS (2009) (8)
- Impact of preoperative glycometabolic status on outcomes in cardiac surgery: Systematic review and meta-analysis. (2021) (8)
- Effects of methimazole treatment on growth hormone (GH) response to GH-releasing hormone in patients with hyperthyroidism. (1990) (8)
- Preliminary observations on the effects of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart (2003) (8)
- A single dose of aztreonam in the prevention of urinary tract infections in elderly catheterized patients. (1990) (8)
- The negative role of subclinical thyrotoxicosis on the outcome of hospitalized geriatric patients. (2002) (8)
- EFFECTS OF CALCITONIN ON GH RESPONSE TO PYRIDOSTIGMINE IN COMBINATION WITH hGHRH (1–29) NH2 IN NORMAL ADULT SUBJECTS (1990) (8)
- Bone Strain Index predicts fragility fracture in osteoporotic women: an artificial intelligence-based study (2021) (8)
- Osteopathy in mild adrenal Cushing's syndrome and Cushing disease. (2021) (8)
- Physiological role of the opioid-cholinergic interaction in growth hormone neuroregulation: effect of sex and food intake. (1997) (8)
- Development of Graves’ hyperthyroidism during the early phase of pregnancy in a patient with pre-existing and long-standing Hashimoto’s hypothyroidism (2006) (8)
- Growth hormone response to thyrotropin releasing hormone and placebo in a group of insulin dependent diabetic patients (1989) (7)
- Variability in the growth hormone response to growth hormone-releasing hormone alone or combined with pyridostigmine in type 1 diabetic patients (1993) (7)
- Effect of arginine on the GHRH-stimulated GH secretion in patients with hyperthyroidism. (1992) (7)
- Author Correction: Acromegaly (2019) (7)
- Hypothalamic regulation of impaired growth hormone secretion in diabetic rats. 2. Studies in spontaneously diabetic BB Worcester rats. (1992) (7)
- Interplay between the intracellular energy sensor AMP-activated protein kinase (AMPK) and the estrogen receptor activities in regulating rat pituitary tumor cell (GH3) growth in vitro (2014) (7)
- Effect of galanin on the growth hormone response to growth hormone-releasing hormone in acromegaly. (1992) (7)
- Bisphosphonates in the treatment of glucocorticoid-induced osteoporosis. (2002) (7)
- The somatostatin subtype-2 receptor antagonist, BIM-23627, improves the catabolic effects induced by long-term glucocorticoid treatment in the rat (2005) (7)
- Glutamate decarboxylase autoimmunity and growth hormone secretion in type I diabetes mellitus. (1997) (7)
- Effect of glucocorticoids on the paradoxical growth hormone response to thyrotropin-releasing hormone in patients with acromegaly. (1995) (7)
- High Prevalence of Vertebral Fractures Associated with Preoperative GH Levels in Patients with recent Diagnosis of Acromegaly. (2022) (7)
- Short-term effect of captopril and nifedipine on micro-albuminuria induced by exercise in hypertensive diabetic patients. (1989) (7)
- Growth hormone treatment in aging: state of the art and perspectives (1997) (7)
- Neuroendocrine Regulation of Growth Hormone Secretion (2000) (6)
- Elevated intraocular pressure in patients with acromegaly (2014) (6)
- Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects. (2000) (6)
- Effects Of Galanin Infusion On Gh Secretion And Ghrh-Induced Gh Release In Prepubertal Male Lambs (1999) (6)
- Effect of the combined administration of galanin and clonidine on serum growth hormone levels in normal subjects and in patients under chronic glucocorticoid treatment. (1994) (6)
- [Growth hormone secretion in heart failure]. (2003) (6)
- Erectile dysfunction as a predictor of asymptomatic coronary artery disease in elderly men with type 2 diabetes (2016) (6)
- Glucocorticoids and bone: cellular, metabolic and endocrine effects. (2004) (6)
- Central alpha-2 adrenergic function in patients with essential hypertension. Comparative study of growth hormone (GH) secretion stimulated by clonidine and GH-releasing hormone. (1990) (6)
- Galanin does not affect the growth hormone-releasing hormone-stimulated growth hormone secretion in patients with hyperthyroidism. (1992) (6)
- Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant (2021) (6)
- Acute effects of octreotide, a long-acting somatostatin analog, on the insulinemic and glycemic responses to a mixed meal in patients with essential obesity. A dose-response study (1994) (6)
- Acute effects of clonidine and growth-hormone-releasing hormone on growth hormone secretion in patients with hyperthyroidism. (1991) (6)
- Short-term glucocorticoid administration decreases both hypothalamic and pituitary galanin synthesis in the adult male rat. (1999) (5)
- Strategies for appraising suspected growth hormone deficiency in the adult (2000) (5)
- Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life (2022) (5)
- Effect of galanin on growth hormone (GH) response to thyrotropin releasing hormone of rat pituitary GH-secreting adenomatous cells (GH1) in culture. (1995) (5)
- Effects of octreotide on autophagy markers and cell viability markers related to metabolic activity in rat pituitary tumor cells (2020) (5)
- Osteoporosis in Human Immunodeficiency Virus Patients - An Emerging Clinical Concern. (2014) (5)
- [Acromegaly: reducing diagnostic delay]. (2016) (5)
- Percutaneous transluminal angioplasty for critical limb ischemia in very elderly diabetic patients (2013) (5)
- Effect of Different Diabetes Mellitus Treatments on Functional Decline and Death in Elderly Adults with Diabetes Mellitus (2013) (5)
- Effects of metoclopramide on the growth hormone response to galanin in normal man. (1993) (4)
- A multicenter collaborative study to measure the prevalence of pituitary disease : methodology and preliminary findings (2005) (4)
- Does growth hormone replacement therapy improve cardiac function? (2007) (4)
- Serum Lipoprotein(a) Is Not Increased in NIDDM Patients With Microalbuminuria (1994) (4)
- Revisiting the endocrine and metabolic manifestations of COVID-19 two years into the pandemic (2022) (4)
- Pituitary gland: Medical therapy for acromegaly: can we predict response? (2009) (4)
- Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly (2021) (4)
- Adrenal schwannoma: why should endocrinologists be aware of this uncommon tumour? (2022) (4)
- Vitamin D and Glucocorticoid-Induced Osteoporosis (2018) (4)
- COVID-19 and hypopituitarism. Experience from an endocrine center in a high-impact area (2020) (4)
- Does growth hormone play a role in chronic heart failure? (2002) (4)
- Vitamin D in the older population: a consensus statement (2022) (4)
- Effect of long-term treatment with bromocriptine on the growth hormone response to galanin in patients with acromegaly. (1993) (4)
- Distinct clinical features of post COVID-19 vaccination early-onset Graves' disease (PoVEO GD). (2022) (4)
- Isradipine decreases exercise-induced albuminuria in patients with essential hypertension. (1993) (4)
- Development of acromegaly in a patient with anorexia nervosa: Pathogenetic and diagnostic implications (2006) (4)
- Acute effects of hydrocortisone on circulating growth hormone levels in patients with acromegaly. (1992) (4)
- Correction to: Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): A Pituitary Society Statement (2018) (3)
- Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience (2022) (3)
- Vertebral fractures at hospitalization predict impaired respiratory function during follow-up of COVID-19 survivors (2022) (3)
- Correction to: Endocrine and metabolic aspects of the COVID-19 pandemic (2021) (3)
- AcroCOVID: An international survey on care for acromegaly during the COVID-19 era (2020) (3)
- Sagit©: A Novel Clinician-Reported Outcome for Managing Acromegaly in Clinical Practice. (2014) (3)
- Development of type II autoimmune polyglandular syndrome in a patient with idiopathic thrombocytopenic purpura. (1988) (3)
- Chapter 10 – Hypothalamic Syndromes∗ (2016) (3)
- Effects of metoclopramide on the paradoxical growth hormone response to galanin in acromegaly. (1993) (3)
- Chapter 9 – The Hypothalamus (2017) (3)
- The Role of Growth Hormone Releasing Hormone (GHRH) and Growth Hormone (GH) in the Onset of Puberty and During Glucocorticoid-Altered Growth (1996) (3)
- Consensus and Controversial Aspects of Vitamin D and COVID-19. (2022) (3)
- Cortisol and the muscle-bone axis: response to comments by Molfino et al. (2015) (3)
- Effects of pasireotide (SOM230) on protein turnover and p70S6 kinase-S6 ribosomal protein signaling pathway in rat skeletal muscle cells (2017) (3)
- Acute Growth Hormone Effects In Human Subjects With Heart Failure (2001) (3)
- 1 year of the Pandemic - How European Endocrinologists responded to the crisis. (2021) (3)
- Quo vadis Endocrine (2011) (3)
- PARACENTRAL ACUTE MIDDLE MACULOPATHY IN CENTRAL RETINAL VEIN OCCLUSION COMPLICATING AMYLOID LIGHT-CHAIN AMYLOIDOSIS (2020) (3)
- The osteo-metabolic phenotype of COVID-19: an update (2022) (2)
- Pituitary testing: a reappraisal (2008) (2)
- Ultrasound and FibroScan® Controlled Attenuation Parameter in patients with MAFLD: head to head comparison in assessing liver steatosis (2022) (2)
- Differential effects of metformin on reductive activity and energy production in pituitary tumor cells compared to myogenic precursors (2020) (2)
- Impact of Testosterone Replacement on the Maturation of the Growth Hormone—IGF-I Axis (1999) (2)
- In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine (2021) (2)
- One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly (2021) (2)
- Acute and chronic galanin administration decreases hypothalamic galanin synthesis in both male and female adult rats: evidence for a long-loop galanin autofeedback. (2000) (2)
- Effect of long-term administration of picotamide on baseline and exercise-induced urinary albumin excretion in patients with type II diabetes mellitus and incipient nephropathy. (1994) (2)
- Introduction to Femtocells (2009) (2)
- Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply. (2022) (2)
- Diagnostic and therapeutic consensus on acromegaly. (2005) (2)
- Primary Headache and Silent Myocardial Ischemia in Patients with Coronary Artery Disease (2013) (2)
- Sensitivity of bone remodeling markers in elderly male patients chronically treated with glucocorticoids. (1999) (2)
- Hexarelin, a novel GHRP-6 analog, counteracts the inhibitory effect of hydrocortisone on growth hormone secretion in acromegaly. (1995) (2)
- OR32-6 Pre-Surgical GH Levels Predict the Risk of Morphometric Vertebral Fracture, Which Is an Early and Frequent Event in the Natural History of Acromegaly (2019) (2)
- Growth hormone deficiency, rapidly reversible during glucocorticoid replacement, in a case of adrenocorticotrophin deficiency. (1988) (2)
- Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization (2023) (2)
- Effects of beta 2-agonists during cardiopulmonary exercise test in COPD patients. (1994) (2)
- Feedback Regulation of Growth Hormone Secretion (2011) (2)
- [Salmon calcitonin nasal spray in the treatment of Paget's disease]. (1989) (2)
- Cardiopulmonary adaptation to exercise after acute weight loss in severely obese subjects. (1995) (2)
- Novel approaches to bone comorbidity in Cushing’s disease: an update (2022) (2)
- Molecular imaging in acromegaly: should clinicians look carefully at developments in the field? (2014) (1)
- Growth hormone in end-stage heart failure (1997) (1)
- Dichotomic Role of Glucocorticoids in the Regulation of Growth Hormone Secretion In Vivo (1994) (1)
- Low Levels of Vitamin D Are Associated With Markers of Immuno-Inflammatory Response and Clinical Outcome in Covid-19 (2021) (1)
- A Single Dose of Aztreonam in the Prevention of Urinary Tract Infections in Elderly Catheterized Patients. (1990) (1)
- Age-related prevalence of vertebral deformities in postmenopausal women treated or untreated with glucocorticoids: A comparison between two Italian national studies. (2003) (1)
- Transmucosal oxygen tension of the clitoris: a new parameter for future investigations of the sexual, metabolic, and cardiovascular health of women (2018) (1)
- Osteoporosis in Human Immunodeficiency Virus Patients – An Emerging Clinical Concern (2014) (1)
- Fat utilization and arterial hypertension in overweight/obese subjects (2013) (1)
- Femtocell Networks and Architectures (2009) (1)
- Acknowledgement of reviewers 2011 (2012) (1)
- Malignancy risk in indeterminate thyroid nodules with Hürthle cells: role of autoimmune thyroiditis (2021) (1)
- Acromegalic osteopathy: An update (2018) (1)
- Effect of galanin and arginine, alone or in combination, on growth hormone secretion in adult patients treated with glucocorticoids. (1993) (1)
- Treatment of end-stage cardiac failure with growth hormone (1997) (1)
- Combined unsupervised and semi-automated supervised analysis of flow cytometry data reveals cellular fingerprint associated with newly diagnosed pediatric type 1 diabetes (2022) (1)
- Subject Index, Vol. 38, 1992 (1992) (1)
- The Potential Impact of Inducing a Restriction in Reimbursement Criteria on Vitamin D Supplementation in Osteoporotic Patients with or without Fractures (2022) (1)
- GROWTH HORMONE IN END-STAGE HEART FAILURE. AUTHOR'S REPLY (1997) (1)
- Subclinical thyrotoxicosis and bone (2018) (1)
- Durable biochemical response and safety with oral octreotide capsules in acromegaly (2022) (1)
- Growth Hormone And The Heart (2012) (1)
- Effects of the combined treatment with AMPK activator and somatostatin-14 on hormone secretion and cell proliferation in cultured GH-secreting pituitary tumor cells (2012) (1)
- SAT-389 Clinical and Biochemical Characterization of Risk Factors for Vertebral Fractures in Patients with Hypoparathyroidism (2020) (1)
- Primary Pituitary Lymphoma (2004) (1)
- High prevalence of adrenal cortical adenomas in patients with cerebral meningiomas (2022) (1)
- A new slow-release formulation of lanreotide (autogel) in patients with active acromegaly: preliminary results of a multicenter, open clinical study (2003) (1)
- LEFT VENTRICULAR STRUCTURAL AND FUNCTIONAL CHARACTERISTICS IN ACROMEGALY: P2.130 (2004) (0)
- Therapeutic decisions in acromegaly according to disease control in patients with acromegaly with or without prior treatment: data from baseline analysis of the SAGIT® validation study (2019) (0)
- Management and outcome of bone metastasis from differentiated thyroid carcinoma in the real life: the M.OS.CA.TI. study (2017) (0)
- Femtocell Implementation Considerations (2009) (0)
- High prevalence of thoracic vertebral fractures in patients with medullary thyroid cancer (2022) (0)
- Hypovitaminosis D and prevalence of vertebral fractures in women with GIO (2009) (0)
- The Dante (Diabetes and Tissue Valve) Study: Diabetes Mellitus Isassociated With Faster Degeneration (2008) (0)
- Insulin-Like Growth Factor 1 and Growth Hormone Levels in Patients with Type 1 Diabetes mellitus (1992) (0)
- Ghrelin and GHS-receptors in rat and human osteoblasts (2004) (0)
- Subject Index, Vol. 36, 1991 (1991) (0)
- European observational study of long-acting pasireotide for uncontrolled acromegaly: ACRONIS study design and rationale (2017) (0)
- Correction to: Pegvisomant in acromegaly: an update (2017) (0)
- Sex-Steroid Effects on Primate Somatotrophs Kenneth C. Copeland (1999) (0)
- Age and severity of hyperthyroidism are determinants of thoracic vertebral fractures in patients with TSH-secreting pituitary adenoma (2018) (0)
- Abstracts of the 6th International Congress on Glucocorticoid-induced Osteoporosis (GIO). October 8-10, 2009. Siena, Italy. (2009) (0)
- Withdrawal from long-acting somatostatin receptor ligand injections in adult patients with acromegaly: Results from the phase 3, randomized, double-blind, placebo-controlled optimal study (2020) (0)
- Predictors of response to medical therapy with pegvisomant and pasireotide lar in SRLs-resistant acromegaly (2020) (0)
- Spontaneous nocturnal growth hormone (GH) secretion and haemodynamic profile in chronic heart failure (CHF) patients (1998) (0)
- Bacteriological and clinical evaluation of cefotetan in the treatment of severe infections in hospitalized patients. (1988) (0)
- Market Issues for Femtocells (2009) (0)
- Somatostatin analogs selective for sub-type 2 and 5 of the somatostatin receptor suppress with different patterns growth hormone (GH) secretion in human GH-secreting adenomas cultured in vitro (1998) (0)
- Subject Index Vol. 88, 2008 (2008) (0)
- HYPERTROPHIC REMODELING OF SUBCUTANEOUS SMALL RESISTANCE ARTERIES IN ACROMEGALIC PATIENTS: P 469 (2004) (0)
- Short-term effects of growth hormone on bone metabolism in a patient with mild hunter disease (1998) (0)
- Poor response to pre-surgical treatment with Somatostatin Receptor Ligands is associated with diabetes in patients with acromegaly (2019) (0)
- SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs (2019) (0)
- Effect of Chronic Growth Hormone Treatment in Heart Failure (2001) (0)
- The effects of pituitary replacement therapies on body composition in adult patients with growth hormone deficiency (2016) (0)
- Galanin modulates GH secretion in prepubertal male lambs. (1998) (0)
- Erratum to: Assessment of the awareness andmanagement of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group (2011) (0)
- Awareness of glucocorticoid-induced osteoporosis: Influence of gender (2009) (0)
- Cone beam computed tomography reveals altered trabecular bone structure in acromegaly (2015) (0)
- LBMON178 2nd Year Outcomes Of The Open-label Extension Of Chiasma Optimal, A Phase 3 Study Of Oral Octreotide Capsules In Acromegaly (2022) (0)
- [Effects of acute administration of nifedipine on exercise-induced microalbuminuria in normotensive patients with type 1 diabetes]. (1990) (0)
- Type II Diabetes Mellitus is Associated with Faster Degeneration of Bioprosthetic Valve: Results from a Propensity Score-Matched Italian Multicenter Study Running title: Lorusso et al.; Bioprosthesis degeneration and diabetes (2011) (0)
- Impact of COVID-19 vaccination on incidence of graves' disease (2022) (0)
- Subject Index, Vol. 37, 1992 (1992) (0)
- Morphometric vertebral fractures are highly prevalent in patients with non-functioning pituitary adenoma and related to older age and hypopituitarism (2020) (0)
- Access point for connection to a LAN/WAN device without using cellular core network (2006) (0)
- Unmet needs on the current medical management of Cushing’s syndrome: results from a Delphi panel of Italian endocrinologists (2023) (0)
- MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study (2020) (0)
- Vitamin D deficiency is a key element in COVID-19 hypocalcemia (2021) (0)
- The GH–IGF-1 axis and GIO (2009) (0)
- Contents, Vol. 38, 1992 (1982) (0)
- Effects of octreotide on hallmarks of autophagy and on parameters related to cell viability and metabolic activity in rat pituitary tumor cells (2019) (0)
- Medical treatment in acromegaly (2021) (0)
- Radiological vertebral fractures in hospitalized elderly patients with heart failure (2012) (0)
- Effect of the GHRP-6 analog hexarelin and arginine alone and combined on GH secretion in patients with active acromegaly (1998) (0)
- Prevention of urinary tract infections in elderly diabetic patients with cefotetan. (1989) (0)
- Access point provides interworking function between core network presence services platform and incompatible mobile device (2006) (0)
- GROWTH OF CHILDREN AFTER LIVER TRANSPLANTATION (LT): LONGITUDINAL AND CROSS-SECTIONAL STUDY (1993) (0)
- The Effects of a Continuous Infusion of Hexarelin on Pulsatile Growth Hormone Release, Growth Axis and Galanin Gene Expression and on the Response of the Growth Axis to Growth Hormone-Releasing Hormone (2000) (0)
- Studies on the cardiovascular activities of growth hormone (2002) (0)
- High prevalence of radiological vertebral fractures in patients with differentiated thyroid carcinoma undergoing L-thyroxine TSH-suppressive therapy (2017) (0)
- Locating a mobile basestation (2007) (0)
- Role of growth hormone in chronic heart failure. Therapeutic implications. (2000) (0)
- Use of a ghrelin agonist to enhance the catabolic effects of glucocorticoids (2007) (0)
- Controlling mobility in cellular networks using home cell hysteresis and neighbour cell offsets and taking neighbour cell loading into account (2009) (0)
- Effect of gonadal status on baseline and after rhGH treatment prevalence of spinal deformities in adult patients with growth hormone deficiency (GHD) (2007) (0)
- Front & Back Matter (2018) (0)
- Preliminary Pages / Contents / Foreword (2002) (0)
- P-30 Growth hormone deficiency and acromegaly have comparable effects on bone mass and osteoporotic fracture risk in adult women (2008) (0)
- O-020. The approximate entropy (ApEn) of GH secretion in young males with hypogonadotropic hypogonadism (HH): A longitudinal study during testosterone replacement (1997) (0)
- Parathyroid Hormone and Glucocorticoid-induced Osteoporosis (2015) (0)
- O-060. Hemodynamic effects of continuous intravenous infusion of growth hormone in patients with severe heart failure (1997) (0)
- Front & Back Matter (2018) (0)
- Neuroendocrinology of Bone Metabolism (2018) (0)
- Appendix: A Brief Guide to Units and Spectrum (2009) (0)
- Physiological role of the neuropeptide galanin in the regulation of anterior pituitary function in man (1992) (0)
- EXPERIENCE Primary Empty (2005) (0)
- Incidence of subclinical hypothyroidism and its influence on cognitive performance and on metabolic aspects in an hospitalized geriatric population. (2002) (0)
- Vitamin D and malabsorptive gastrointestinal conditions: A bidirectional relationship? (2023) (0)
- Growth Hormone Secretion In Congestive Heart Failure (2001) (0)
- Effects on glucose metabolism of high-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy (2010) (0)
- New tools for bone health assessment in secreting pituitary adenomas (2023) (0)
- Increased prevalence of radiological spinal deformities in adult patients with untreatedgrowth hormone (GH) deficiency (2005) (0)
- Effect of the neuropeptide galanin on circulating growth hormone levels in different pathophysiological conditions characterized by altered GH secretion (1992) (0)
- Radiological vertebral fractures in patients with acromegaly treated with L-thyroxine (2016) (0)
- Editorial overview: Endocrinology of bone (2018) (0)
- The impact of body composition on vertebral fractures during aromatase inhibitors therapy: A cross-sectional study. (2018) (0)
- Summary: The Status and Future of Femtocells (2009) (0)
- Hyperprolactinemia is a risk factor for radiological vertebral fractures in post-menopausal women (2011) (0)
- Best Practice & Research Clinical Endocrinology & Metabolism (2009) (0)
- COMPARATIVE EFFECT OF GROWTH HORMONE (GH)-RELEASING HORMONE(GHRH) AND THE NEUROPEPTIDE GALANIN ON GH SECRETION IN SLOWLY GROWING LIVER TRANSPLANTED CHILDREN UNDER CHRONIC GLUCOCORTOCOID THERAPY (1993) (0)
- Direct effect of leptin of GH gene expression in adult pigs (2001) (0)
- AB0831 PERSPECTIVE ON THE CLINICAL PRACTICE MANAGEMENT OF HYPOVITAMINOSIS D FROM A MEETING OF ITALIAN EXPERTS (2019) (0)
- Patients receiving a range of doses of prior injectable somatostatin receptor ligands respond to oral octreotide in the treatment of acromegaly: Results from the phase 3 optimal study (2020) (0)
- Pituitary tumor centers of excellence for Cushing’s disease (2022) (0)
- MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly (2020) (0)
- MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study (2020) (0)
- Growth Hormone and Exercise Performance (2001) (0)
- SIM interface of a base station allows LAN-connected device to appear as a mobile device to the cellular core network (2006) (0)
- Effects of pegvisomant and pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with first-line somatostatin analogs (2019) (0)
- Determinants of spinal deformities in adult patients with untreated growth hormone deficiency (GHD) (2008) (0)
- Diabetes mellitus as adjunctive risk factor for vertebral fractures in men with acromegaly (2011) (0)
- Contents Vol. 88, 2008 (2008) (0)
- Growth hormone in end-stage heart failure (multiple letters) [6] (1997) (0)
- Effect of pyridostigmine on the hydrocortisone-mediated decrease of circulating growth hormone levels in acromegaly. (1994) (0)
- Front & Back Matter (2018) (0)
- PARATHYROID HORMONE TRANSLATIONAL AND CLINICAL ASPECTS Clinical and Biochemical Characterization of Risk Factors for Vertebral Fractures in Patients with Hypoparathyroidism (2020) (0)
- High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial (2009) (0)
- Body mass index is a biomarker of resistance to active vitamin D but not to calcium supplementation, in patients with hypoparathyroidism (2019) (0)
- Prevalence of vertebral fractures in postmenopausal glucocorticoid-treated women: A national study. (2003) (0)
- Metabolism of glucose in patients with acromegaly treated with Pegvisomant and/or Pasireotide LAR after resistance to first generation somatostatin receptor ligands (2020) (0)
- Predictive value of the assessment of risk factors of osteoporosis on bone ultrasonometric features in a normal population:data from boss study (brescia osteoporosis stratification of risk study) (2005) (0)
- Diagnosis of active acromegaly : is it time to amend the consensus of opinions? (2005) (0)
- Evaluation of the outcome of neurosurgical treatment of acromegaly: Relationship between IGF-I and growth hormone at baseline and after oral glucose tolerance test (OGTT) levels (1998) (0)
- Modern approach to resistant acromegaly (2023) (0)
- HYPOTHALAMIC CONTROL OF GROWTH HORMONE (GH) SECRETION COMBINED ADMINISTRATION OF GH-RELEASING HORMONE AND HEXARELIN, A NOVEL GHRP-6 ANALOG. IN TYPE I DIABETIC MEN: EFFECT OF THE (1996) (0)
- Influence of glucocorticoid replacement treatment on risk of vertebral fractures in patients with hypopituitarism (2009) (0)
- ODP594 Vitamin D Levels At Hospital Admission Predict Severity Of Covid-19: A Controlled Prospective Study (2022) (0)
- Low 25(OH) vitamin D levels are associated with Long COVID syndrome in COVID-19 survivors (2023) (0)
- Radio Issues for Femtocells (2009) (0)
- Preliminary Testing of the Sagit Tool: A Tool to Help Endocrinologists in Their Management of Patients with Acromegaly in Clinical Practice (2013) (0)
- Low vitamin D levels are associated with Long COVID syndrome in COVID-19 survivors. (2023) (0)
- Front & Back Matter (2018) (0)
- Effect of age on beta-cell response to exogenous glucagon in man. (1989) (0)
- Chapter 34 – Glucocorticoid-induced Osteoporosis (2010) (0)
- Femtocell Standards and Industry Groups (2009) (0)
- PMON166 Safety Comparison of 40- vs 60-mg/day Doses of Oral Octreotide Capsules for Treatment of Acromegaly in the CHIASMA OPTIMAL Trial (2022) (0)
- RANKL inhibition as a targeted approach in the management of osteoporosis (2009) (0)
- 30 ERECTILE DYSFUNCTION AS ADDITIONAL CRITERIUM TO IMPROVE GUIDELINES FOR SCREENING SILENT MYOCARDIAL ISCHEMIA IN DIABETES (2008) (0)
- Business and Service Options for Femtocells (2009) (0)
- Correction to: Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly (2018) (0)
- A Delphi panel of Italian endocrinologists to define the unmet needs on the current management of Cushing's Syndrome (2022) (0)
- GH/IGF-I and Bone (2018) (0)
- Effect of galanin on the growth hormone (GH) response to thyrotropin-releasing hormone (TRH) in patients with acromegaly (1994) (0)
- Acknowledgement of reviewers 2013 (2014) (0)
- MON-529 Body Mass Index Predicts Resistance To Active Vitamin D In Patients With Hypoparathyroidism (2019) (0)
- Vitamin D status in Armenian women: a stratified cross-sectional cluster analysis (2021) (0)
- Small Cell Background and Success Factors (2009) (0)
- Front & Back Matter (2018) (0)
- Correction: Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era (2021) (0)
- Pefloxacin in the treatment of acute severe infections in hospitalized patients. Clinical and bacteriological evaluation. (1989) (0)
- [Addison's disease and hypothyroidism]. (1988) (0)
- Sarcopenic obesity research perspectives outlined by the sarcopenic obesity global leadership initiative (SOGLI) - Proceedings from the SOGLI consortium meeting in rome November 2022. (2023) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Andrea Giustina?
Andrea Giustina is affiliated with the following schools:
